A new era for ribonucleoside reductase inhibition

Leukemia Research

Volumn 31, Issue 9, 2007, Pages 1163-1164

  Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hydroxyurea resistance; Refractory leukemia; Ribonucelotide reductase inhibitors; Triapine

Indexed keywords

1 ACETYL 1,2 BIS(METHYLSULFONYL) 2 (2 CHLOROETHYL)HYDRAZINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; HYDROXYUREA; RIBONUCLEOSIDE REDUCTASE INHIBITOR; TRIAPTINE; UNCLASSIFIED DRUG; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; PYRIDINE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; THIOSEMICARBAZONE DERIVATIVE;

BINDING SITE; CANCER INHIBITION; CELL PROLIFERATION; DNA SYNTHESIS; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENTIATION; EDITORIAL; ENZYME ACTIVITY; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; NOTE;

ENZYME INHIBITORS; HUMANS; LEUKEMIA; PYRIDINES; RIBONUCLEOTIDE REDUCTASES; THIOSEMICARBAZONES;

EID: 34249909530     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.02.010     Document Type: Editorial

References (17)

1. Tsimberidou A.M., Alvarado Y., and Giles F.J. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2 (2002) 437-448
2. Reichard P. From RNA to DNA, why so many ribonucleotide reductases?. Science 260 (1993) 1773-1777
3. Thelander L., and Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 48 (1979) 133-158
4. Cory J.G. Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul 27 (1988) 437-455
5. Cory J.G., and Carter G.L. Drug action on ribonucleotide reductase. Adv Enzyme Regul 24 (1985) 385-401
6. Li J., Zheng L.M., King I., Doyle T.W., and Chen S.H. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr Med Chem 8 (2001) 121-133
7. Barker C.A., Burgan W.E., Carter D.J., et al. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res 12 (2006) 2912-2918
8. Giles F.J., Fracasso P.M., Kantarjian H.M., et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27 (2003) 1077-1083
9. Beckloff G.L., Lerner H.J., Frost D., Russo-Alesi F.M., and Gitomer S. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. Cancer Chemother Rep 48 (1965) 57-58
10. Gwilt P.R., and Tracewell W.G. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 34 (1998) 347-358
11. Bianchi V., Pontis E., and Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261 (1986) 16037-16042
12. Feun L., Modiano M., Lee K., et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 50 (2002) 223-229
13. Yen Y., Margolin K., Doroshow J., et al. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54 (2004) 331-342
14. Wadler S., Makower D., Clairmont C., Lambert P., Fehn K., and Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22 (2004) 1553-1563
15. Yee K.W., Cortes J., Ferrajoli A., et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30 (2006) 813-822
16. Gojo I., Tidwell M.L., Greer J., et al. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 31 (2007) 1183-1191
17. Finch R.A., Liu M., Grill S.P., et al. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59 (2000) 983-991